The management of the different subtypes of BC is mainly determined by the expression of peculiar receptors, particularly the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) [2]. This evidence concerns the gene ERBB2 and breast cancer.